You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,895,441


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,895,441
Title:Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists
Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
Inventor(s): Maecker; Heather (Palo Alto, CA), Irving; Bryan (San Francisco, CA)
Assignee: GENENTECH, INC. (South San Francisco, CA)
Application Number:14/556,774
Patent Claims:1. A method for treating or delaying progression of colorectal cancer in an individual comprising administering to the individual an effective amount of an anti-PD-L1 antibody, oxaliplatin, leucovorin and 5-FU, wherein the method further comprises administering bevacizumab, wherein the anti-PD-L1 antibody comprises a heavy chain variable region and a light chain variable region, wherein: (a) the heavy chain variable region comprises an HVR-H1, HVR-H2 and HVR-H3, and wherein: (i) the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 15; (ii) the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 16; (iii) the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 3; and (b) the light chain variable region comprises an HVR-L1, HVR-L2 and HVR-L3, and wherein: (iv) the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 17; (v) the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 18; and (vi) the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 19.

2. The method of claim 1, wherein the anti-PD-L1 antibody is a monoclonal antibody.

3. The method of claim 1, wherein the anti-PD-L1 antibody is an antibody fragment selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and (Fab').sub.2 fragments.

4. The method of claim 1, wherein the anti-PD-L1 antibody is a humanized antibody.

5. The method of claim 1, wherein the anti-PD-L1 antibody comprises a heavy chain variable region and a light chain variable region, wherein: (a) the heavy chain variable region amino acid sequence has at least 90% sequence identity to the heavy chain variable region amino acid sequence of SEQ ID NO:20, and (b) the light chain variable region amino acid sequence has at least 90% sequence identity to the light chain variable region amino acid sequence of SEQ ID NO:21.

6. The method of claim 5, wherein: (a) the heavy chain variable region amino acid sequence has at least 95% sequence identity to the heavy chain variable region amino acid sequence of SEQ ID NO:20, and (b) the light chain variable region amino acid sequence has at least 95% sequence identity to the light chain variable region amino acid sequence of SEQ ID NO:21.

7. The method of claim 6, wherein: (a) the heavy chain variable region amino acid sequence has at least 99% sequence identity to the heavy chain variable region amino acid sequence of SEQ ID NO:20, and (b) the light chain variable region amino acid sequence has at least 99% sequence identity to the light chain variable region amino acid sequence of SEQ ID NO:21.

8. The method of claim 7, wherein (a) the heavy chain variable region amino acid sequence has at least 99% sequence identity to the heavy chain variable region amino acid sequence of SEQ ID NO:20, and (b) the light chain variable region comprises the amino acid sequence of SEQ ID NO:21.

9. The method of claim 8, wherein the anti-PD-L1 antibody further comprises a human IgG1 constant region.

10. The method of claim 9, wherein the anti-PD-L1 antibody comprises an effector-less Fc mutation, wherein the effector-less Fc mutation is N297A.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.